Skip to main content
. Author manuscript; available in PMC: 2022 Feb 1.
Published in final edited form as: Maturitas. 2020 Dec 2;144:37–44. doi: 10.1016/j.maturitas.2020.10.018

Table 1.

Patient demographics and clinical characteristics

Arm
Treatment
(N=10)
Sham
(N=8)
Total
(N=18)
P-value
Age at On Study 0.92901
 N 10 8 18
 Mean (SD) 56.0 (11.17) 56.8 (5.95) 56.3 (8.98)
 Median 59.5 56.5 57.5
 Range 35.0, 72.0 45.0, 63.0 35.0, 72.0
Prior Radiation, n (%) 0.34162
 Prior Radiation 3 (30.0%) 5 (62.5%) 8 (44.4%)
 No Prior Radiation 7 (70.0%) 3 (37.5%) 10 (55.6%)
Type of cancer, n (%) 1.00002
 Cervical 2 (20.0%) 1 (12.5%) 3 (16.7%)
 Endometrial 4 (40.0%) 3 (37.5%) 7 (38.9%)
 Ovarian 3 (30.0%) 3 (37.5%) 6 (33.3%)
 Vaginal 1 (10.0%) 0 (0.0%) 1 (5.6%)
 Vulvar 0 (0.0%) 1 (12.5%) 1 (5.6%)
Histology, n (%) 0.17532
 Adenocarcinoma 6 (60.0%) 3 (42.9%) 9 (52.9%)
 Other 3 (30.0%) 0 (0.0%) 3 (17.6%)
 Serous Carcinoma 1 (10.0%) 2 (28.6%) 3 (17.6%)
 Squamous Cell Carcinoma 0 (0.0%) 2 (28.6%) 2 (11.8%)
 Missing 0 1 1
Stage, n (%) 0.71902
 I 0 (0.0%) 1 (12.5%) 1 (5.9%)
 IA 5 (55.6%) 3 (37.5%) 8 (47.1%)
 IB 1 (11.1%) 1 (12.5%) 2 (11.8%)
 II 1 (11.1%) 1 (12.5%) 2 (11.8%)
 IIB 1 (11.1%) 0 (0.0%) 1 (5.9%)
 III 0 (0.0%) 2 (25.0%) 2 (11.8%)
 IIIB 1 (11.1%) 0 (0.0%) 1 (5.9%)
 Missing 1 0 1
Chemotherapy, n (%) 0.58462
 No 3 (33.3%) 1 (14.3%) 4 (25.0%)
 Yes 6 (66.7%) 6 (85.7%) 12 (75.0%)
 Missing 1 1 2
Surgery, n (%) 1.00002
 No 1 (10.0%) 0 (0.0%) 1 (5.6%)
 Yes 9 (90.0%) 8 (100.0%) 17 (94.4%)
Vaginal Lubricant Use, n (%) 0.15152
 No 7 (87.5%) 1 (33.3%) 8 (72.7%)
 Unknown 0 (0.0%) 1 (33.3%) 1 (9.1%)
 Yes 1 (12.5%) 1 (33.3%) 2 (18.2%)
Missing 2 5 7
Vaginal Moisturizer Use, n (%) 0.09092
 No 8 (100.0%) 2 (50.0%) 10 (83.3%)
 Unknown 0 (0.0%) 2 (50.0%) 2 (16.7%)
 Missing 2 4 6
Vaginal Estrogen Use, n (%) 0.05172
 No 8 (88.9%) 1 (25.0%) 9 (69.2%)
 Unknown 0 (0.0%) 2 (50.0%) 2 (15.4%)
  Yes 1 (11.1%) 1 (25.0%) 2 (15.4%)
 Missing 1 4 5
1

Kruskal-Wallis p-value

2

Fisher Exact p-value